Our Team

HanchorBio

HanchorBio is pioneering the development of fusion protein for immuno-therapy. The HanchorBio team is developing next generation biologic therapeutics to address the growing immuno-oncology market. HanchorBio’s modular approach of combination therapy has the potential to fundamentally transform the therapeutic modulation of the immune system.

VISIT SITE

Inmagene Biopharmaceuticals

Inmagene Biopharmaceuticals is a clinical stage pharmaceutical company with different in-licensed pipeline focusing on immune-related diseases.

VISIT SITE

Oncxerna

Oncxerna is an oncology therapeutics company focusing on clinical programs that modify the immune system to enhance efficacy of current standards of care and emerging immunotherapy agents.

VISIT SITE

Kindstar Global

Kindstar Globalgene Technology, Inc. a large high-end esoteric testing service provider in China, is committed to leading the progress of esoteric testing technologies and services in China and promoting the development and improvement of specialized diagnosis and treatment and personalized medicine.

VISIT SITE

Zhaoke Ophthalmology

Zhaoke Ophthalmology, a Guangzhou based biotech company, specializeds in developing a porfolio of drugs to treat various eye diseases .

VISIT SITE

Maavrx

Maaverx is a gene therapy company basd in London. Maaverx focuses on developing treatement for Parkinson’s Disease.

VISIT SITE

Tactiva Therapeutics

Tactiva Therapeutics is an immuno-oncology company utilizing an innovative approach to adoptive cell therapy.  Tactiva Therapeutics has identified a library of T cell receptors (TCRs) that specifically recognize and attack cancer cells.

VISIT SITE

Evox Therapeutics

Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of therapeutics.

VISIT SITE

Windtree Therapeutics

Windtree is a global acute care company specializing in cardiovascular and respiratory diseases.  The company has four mid-to-late cliniacal stage assets and multiple preclinical assets and programs.  Windtree is headquartered in Warrington, PA with pre-clinical operations in Taipei and Milan.

VISIT SITE

APMTD

APMTD specializes in designing and developing minimally invasive device solutions for unmet medical needs such as stroke, heart failure, eCPR and peripheral vascular diseases. The company's local drug delivery system TAPAS and targeted hypothermia induction system DuoFlo have been approved for commercialization in US, China, EU, Australia and Taiwan region.

VISIT SITE

TriArm Therapeutics

TriArm Therapeutics develops most unique cell therapies for both blood and solid tumors. TriArm established advanced technologies such as Beauty11, DEACT and HiSAFE platform, in which can bring out a series of innovative products with low manufacturing cost, improved safety, and ensured efficacy.

VISIT SITE

GLAdiator

GLAdiator is an early-stage oncology company with a proprietary cancer drug delivery platform that uses the naturally occurring gamma-carboxyglutamic-acid domain associated with human coagulation factors to treat diseased cells through the targeted recognition of phospholipid phosphatidylserine which is believed to be a global immunosuppressive signal.

VISIT SITE

BioGraph 55

BioGraph 55 focuses on target discovery and drug development in immuno-oncology by leveraging a proprietary and validated spatial-mapping technology platform that collects biological information from cellular interactions in their native environment and integrates this information with other data to identify novel drug targets.

VISIT SITE

Actym Therapeutics

Actym Therapeutics is an early-stage oncology company with a novel bacterial-based immunotherapy platform that can achieve tumor-specific multi-drug delivery while still utilizing from flexible plasmid design and efficient manufacturing.

VISIT SITE

Apeiron

Apeiron is a small molecule biotech company based in Shanghai and San Francisco Bay Area, with significant collaborations with Exscientia (NASDAQ: EXIA), an AI drug discovery company based in the UK.

VISIT SITE

Domain Therapeutics

Domain Therapeutics, a biopharmaceutical company operating in France and Canada, is dedicated to the discovery and development of new drug candidates targeting G Protein-Coupled Receptors (GPCRs). The company focuses on developing high-value drug candidates to tackle GPCR-mediated immunosuppression in immune-oncology.

VISIT SITE

ST Phi Therapeutics

ST Phi Therapeutics,is a Hangzhou based biotech company focused on universal cell therapy development in solid tumors, founded by Dr. Lingfeng Liu.  It is the first biotech to enable off-the-shelf CAR-T therapy featuring NK cell characteristics that is less tumor associated antigen dependent, showing initial safety and efficacy in liver cancer patients.

VISIT SITE
copyright @ 2021 Panacea Venture all rights reserved.